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Abstract: Prostate tumour growth is almost always dependent upon the androgen receptor pathway and hence therapies 
aimed at blocking this signalling axis are useful tools in the management of this disease. Unfortunately such therapies in-
variably fail; and the tumour progresses to an “androgen-independent” stage. In such cases androgen receptor expression 
is almost always maintained and much evidence exists to suggest that it may still be driving growth. One mechanism by 
which the receptor is thought to remain active is mutation. This review summarises the present data on androgen receptor 
mutations in prostate cancer, and how such substitutions offer a growth advantage by affecting cofactor interactions or by 
reducing ligand specificity. Such alterations appear to have a subsequent effect upon gene expression suggesting that tu-
mours may “behave” differently dependent upon the ligand promoting growth and if a mutation is present. 
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1. THE ANDROGEN RECEPTOR 
  The Nuclear Receptor family is the largest group of eu-
karyotic transcription factors, with 48 human receptors pres-
ently described [1]. The androgen receptor (AR) is a steroid 
receptor; a sub-family of receptors characterised as ligand 
dependent, sequence specific transcription factors [2] and 
like other nuclear receptors the AR has a modular structure 
(reviewed in [1]) - see Fig. (1). The AR gene is situated at 
Xq11-12 and consists of 8 exons with exon 1 encoding the 
N-terminal domain and the entire 5’ untranslated region, 
exons 2 and 3 encoding the DNA binding domain (DBD) 
and exons 4-8 encoding the “hinge” region and ligand bind-
ing domain (LBD) [3]. 
1.1. Activation Function 1 
  The N-terminal domain contains activation function-1 
(AF-1), which is composed of 2, to some extent separable, 
transcription activation units (TAUs) – TAU1 and TAU5 
(residues 1-485 and 360-528 respectively) [3]. Although the 
locations of the TAUs overlap, the cores of these units (con-
taining over 80% activity) are in separate regions and have 
individual characteristics. TAU1 appears to be important in 
ligand-dependent activation, whereas deletion of the LBD 
reduces the activity of TAU1; instead, most activity is via 
TAU5 [4].  
  A polymorphic polyglutamine (CAG) tract is present in 
the N-terminus of the AR and ranges from 8 to 30 repeats in 
normal individuals, with a modal length of 20 [5]. The rare 
neuromuscular disorder, spinal and bulbar muscular atrophy 
(SBMA or Kennedy’s disease), is caused by expansion of the 
CAG tract to more than 40 repeats. Receptors with this ex-
pansion form nuclear aggregates and cause neurodegredation 
through  a  toxic  gain-of-function  mechanism  [6,  7].  The  
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mechanism of this toxicity is not clear, but it has been postu-
lated that abnormal expression of caspases, in response to 
receptor aggregates, may be involved (reviewed in [7]). 
Longer polyglutamine tract length also results in decreased 
AR transcriptional activity in vitro [8], whereas shorter CAG 
repeats has been linked to increased activity and subsequent 
increased risk of prostate cancer [9].  
  The N-terminal region of the AR appears to be highly 
unstructured. A more folded and subsequently proteosome 
resistant conformation can be achieved by incubation with 
folding-inducing solvents (such as trimethylamine-N oxide, 
TMAO), and also by binding of the cofactor TFIIF (Tran-
scription Factor IIF) [10, 11]. This increased folding is im-
portant in transcriptional activity since it enhances recruit-
ment of accessory proteins such as SRC1 (Steroid Receptor 
Coactivator 1) [12].  
1.2. DNA Binding Domain 
  The DNA binding domains (DBD) of nuclear receptors 
have high sequence homology, with differences in the amino 
acids that contact the DNA eliciting specificity [13]. The 
DBD contains 9 cysteine residues, 8 of which form 2 tetra-
hedral conformations each around a single zinc atom, form-
ing 2 zinc finger-like modules through which the receptors 
interact with DNA [14]. The first zinc finger contains the P-
box (Gly
577, Ser
578 Cys
579, Lys
580 and Val
581 of the AR), 
which from studies using hybrid receptors has been found to 
confer receptor response element specificity [13, 15-17]. The 
second zinc finger appears to stabilise binding via interaction 
of the D-box (amino acids Ala
596, Ser
597, Lys
598, Asn
599 and 
Asp
600) with the sugar-phosphate backbone of DNA [17]. 
1.3. Hinge 
  The hinge region of nuclear receptors was originally 
thought to be a flexible linker region important in DNA 
binding and dimerisation. Detailed analysis of the region, 
however, has demonstrated that the region plays a more di-
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tants, Haelens et al. found that amino acids 629-636 of the 
hinge region are also important in nuclear localisation, pro-
tein interactions and the ligand dependent N-/C-terminal 
interaction [19]. 
1.4. Ligand Binding Domain/Activation Function 2 
  The ligand binding domain of nuclear receptors is com-
prised of 11-12 -helices and 1 -sheet that fold to form a 
triple-layered anti-parallel -helical sandwich. This folding 
forms a hydrophobic pocket into which the ligand fits; crys-
tallographic analysis of various members of the family have 
revealed a highly conserved structure with the exact dimen-
sions of the pocket varying according to the cognate ligand 
[20-30]. Ligand binding promotes the relocalisation of helix 
12, which realigns to create a surface consisting of helices 3, 
4, 5 and 12 that is important in cofactor binding [31-33]. 
  The predominant activation function in the AR appears to 
be AF-1, since deletion of AF-2 and the LBD results in a con-
stitutively active receptor with similar activity to the wild-
type receptor in the presence of agonist [34, 35]. Recently, 
however, it has been demonstrated that AF-2 plays a signifi-
cant role in chromatin and hence its importance in transcrip-
tional regulation may have been underestimated [36].  
1.5. The Androgen Receptor Pathway 
  The unliganded AR is predominantly cytoplasmic [37, 
38] and associated with a large heterocomplex, including 
chaperone and heat-shock proteins, that holds the receptor  
in a ligand binding competent state [39] (Fig. 2). Ligand 
binding promotes dissociation from this complex, dimerisa-
tion, nuclear localisation and intra- and inter-receptor inter-
actions [40]. The AR, like several other nuclear receptors 
(e.g. oestrogen receptor  and the progesterone receptor) 
undergoes a ligand-dependent N- and C-terminal interaction. 
This interaction is predominantly mediated by an N-terminal 
23FQNLF
27 motif interacting with the AF-2 cofactor-inter- 
action surface. It is important for transcriptional activity 
since it increases receptor stability, reduces ligand off-rate 
and creates interaction sites for accessory proteins [41, 42].  
  The AR has been found to interact with a large number of 
proteins that enhance receptor activity, termed coactivators. 
Such factors often have, or recruit proteins that have, histone 
acetyltransferase activity and are hence believed to increase 
receptor activity in part by relaxing chromatin structure. The 
best characterised are the p160 family of coactivators, con-
sisting of SRC-1/NCOA1 (Steroid Receptor Coactivator-1 / 
Nuclear Receptor Coactivator 1), SRC-2/NCOA2/TIF-
2/GRIP-1 (Transcriptional Intermediary Factor 2 / Glucocor-
ticoid Receptor Interacting Protein-1) and SRC-3/NCOA3/ 
AIB1/pCIP/RAC-3 (Amplified In Breast Cancer-1 Protein / 
CBP-Interacting Protein / Receptor-Associated Coactivator 
3) [43]. Many coactivators interact with nuclear receptors via 
LxxLL motifs (where L is leucine and x is any amino acid), 
which form an amphipathic -helix that binds directly to the 
hydrophobic AF-2 coactivator groove [44, 45]. Unlike the 
other steroid receptors, the AR can also interact with and has 
higher affinity for phenylalanine rich motifs, for example the 
FQNLF motif found in the N-terminus of the AR and those 
found in some coactivators, for example Androgen Receptor 
Activator 70 (ARA70) [46, 47]. Study of the crystal structure 
of the AR AF-2 surface has demonstrated the coactivator 
groove to be much deeper than that found in the other steroid 
receptors [47, 48]. This deeper groove appears to be able to 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Frequency and location of androgen receptor mutations associated with prostate cancer. The location and frequency of differ-
ent single base mutations are given, highlighting where these substitutions lie in relation to functional domains of the androgen receptor. 20    Current Genomics, 2009, Vol. 10, No. 1  Brooke and Bevan 
accommodate the bulkier phenylalanine residues hence ex-
plaining the differences in receptor-interaction motif speci-
ficity. 
  Conversely, corepressor proteins have also been identi-
fied, for example Nuclear Co-Repressor Protein (NCoR) and 
Silencing Mediator for Retinoid and Thyroid Hormone Re-
ceptor (SMRT), which have been found to bind to both ago-
nist- and antagonist-bound receptors and reduce their activ-
ity. There are multiple mechanisms by which corepressors 
appear to inhibit receptor signalling - for example, via re-
cruitment of histone deacetylases to condense chromatin 
structure, and via nuclear exclusion of the receptor [49]. 
  The AR interacts with DNA via response elements lo-
cated within the regulatory regions of target genes. The AR 
has been found to bind strongly to an inverted repeat of a 5’-
TGTTCT-3’ half site (termed the core recognition sequence) 
separated by 3 base pairs [50-52]. This consensus sequence 
is not specific for the AR, but also acts as a response element 
for glucocorticoid, mineralocorticoid and progesterone re-
ceptors [51, 53, 54]. Recently a second class of response 
elements, which appear to be highly AR specific, have been 
described and these consist of a direct repeat of the core rec-
ognition sequence. Both inverted and direct repeats have 
been found in the regulatory regions of many androgen re-
sponsive genes, such as PSA (Prostate Specific Antigen) and 
SC (Secretory Component) [55-58].  
2. THE PROSTATE 
  The prostate is a secretory gland located at the base of the 
bladder with a composition that is approximately 70% glan-
dular elements (acini that empty into multiple small duc-
tules) and 30% fibromuscular stroma [59]. The stroma is 
continuous with the capsule that encases the prostate, con-
sisting of collagen, elastin and smooth muscle. The muscle 
contracts upon ejaculation, forcing prostatic secretions, im-
portant in events such as semen coagulation and liquefaction, 
into the urethra [60]. The first link between androgens and 
prostate development was made by John Hunter, who in 
1786 noted that the size of the gland in castrated animals was 
significantly reduced compared to that in intact animals [61]. 
The prostate has since been demonstrated to develop from 
the urogenital sinus in response to fetal testicular androgens 
(reviewed in [62]). At maturity growth of the gland ceases, 
but androgens continue to play an important role in prostate 
function. In some men, androgen dependent growth of the 
prostate resumes, resulting in benign prostatic hyperplasia 
(BPH), premalignant prostatic intraepithelial neoplasia (PIN) 
or prostate cancer (PCa).  
2.1. Prostate Cancer 
  Prostate cancer is the most common cancer in men in the 
United Kingdom, with approximately 35,000 men diagnosed 
every year [63]. The biggest risk factor in prostate cancer is 
age, with more than 60% of cases occurring in men over 75. 
Incidence of prostate cancer have been consistently rising 
and hence it is likely that prostate cancer will overtake lung 
cancer as the leading cause of cancer related death in West-
ern men. 
2.2. Treatment 
  Approximately 25% of prostate cancer patients have or-
gan-confined disease upon presentation and for such patients 
radical prostatectomy (complete removal of the prostate) 
offers the highest likelihood of long-term disease free sur-
vival [64]. Unfortunately the majority of patients present 
with disease that has spread from the prostate capsule and 
hence surgery is not an option. Since the growth of the pros-
tate is almost always dependent upon the AR pathway, 
therapies to treat non-organ confined disease often target this 
signalling axis. Up to the 1950s orchiectomy was routinely 
 
 
 
 
 
 
 
Fig. (2). Hormone therapy failure caused by AR mutation. (1) The unliganded AR exists in the cytoplasm associated with a large hetero-
complex that holds it in a ligand binding competent state. (2) Upon ligand binding the receptor dimerises, translocates to the nucleus where it 
binds DNA and promotes gene transcription via the recruitment of accessory proteins, such as coactivators. (3) Non organ-confined prostate 
cancer is usually treated by blocking the AR pathway. This is achieved by blocking the production of androgen (using LHRH analogues) 
and/or antiandrogens. (4) Antiandrogens bind to the AR but do not promote an active conformation and instead block receptor function, at 
least in part, by promoting the recruitment of corepressors to the regulatory regions of target genes. (5) This therapy selects for cells that have 
mechanisms by which the tumour can grow in the androgen depleted environment. One such mechanism is that of AR mutation and in some 
cases these mutants provide a growth advantage because they reduce the ligand specificity of the receptor. Hence other ligands, such as the 
antiandrogens being used in treatment, are now able to promote an active conformation, the recruitment of coactivators and subsequently 
gene expression. The Role of Androgen Receptor Mutations in Prostate Cancer Progression  Current Genomics, 2009, Vol. 10, No. 1    21 
used to reduce circulating levels of androgens, since the 
main site of production is the testis. Since then chemical 
castration has been the preferred method and this is achieved 
by using leuteinising hormone releasing hormone (LHRH) 
analogues, which act via the pituitary-hypothalamus signal-
ling axis to block androgen production. These analogues 
successfully reduce circulating levels of testosterone by 
more than 95%, but levels of adrenally produced androgen 
precursors such as dehydroepiandrosterone remain unaf-
fected, and these can be effectively converted in the prostate 
into the potent androgen dihydrotestosterone [65, 66]. Hence 
androgen levels within the prostate may only be reduced by 
approximately 60% and for this reason antiandrogens are 
often also administered to reach “total androgen blockade”.  
  Antiandrogens are ligands that can bind to the AR and 
hold it in an inactive state. The exact mechanisms of antian-
drogen action are not completely understood, but they appear 
to function at least in part via the recruitment of corepressors 
to the regulatory regions of target genes. Shang et al. for 
example, found that the corepressors NCoR and SMRT were 
recruited to the promoter region of the PSA gene following 
treatment with the antiandrogen Bicalutamide [67]. In con-
trast, coactivators such as SRC1 were present following 
treatment with an agonist. 
2.3. Androgen Independence 
  Hormone therapy is successful in the majority of patients, 
resulting in both symptomatic and pathological improve-
ment. Unfortunately this therapy invariably fails after a me-
dian of 2 years and the tumour progresses to a more aggres-
sive “androgen-independent” stage. To call this stage andro-
gen- or hormone- independent is perhaps misleading since in 
most cases the AR is expressed and much data suggests that 
the receptor is still functional. Several mechanisms have 
been proposed to explain how the AR may still be driving 
growth even in the androgen-depleted environment and these 
include AR amplification, alterations in cofactor levels and 
AR mutation [68].  
2.4. AR mutations  
  In early stages of prostate cancer mutations of the AR are 
rare but their frequency is significantly increased in ad-
vanced, androgen-independent tumours suggesting that AR 
mutations play a role in tumour progression [69-72]. Marcelli 
et al. for example, found that out of 99 patients in the early 
stages of prostate cancer, none had mutation(s) in the AR 
coding sequence [70]. In advanced stages of the disease, 
however, 8 out of the 38 patients studied (21%) with more 
advanced disease, were found to have mutation(s) of the AR.  
  Over 70 different somatic missense AR mutations have 
been described in patients with prostate cancer [73]. Shi  
et al. compared the activity of 44 such mutations and found 
that 20 had a gain of function [74]. Cells carrying such muta-
tions are likely to provide a growth advantage in the andro-
gen-depleted environment and hence be selected for during 
therapy. The mechanisms by which such mutations provide a 
growth advantage appear to be, at least in part, due to altera-
tions in cofactor recruitment or by reducing ligand specific-
ity.  
2.4.1. Alterations in Cofactor Binding 
  Although most mutations lie in the LBD, more than 30 
substitutions associated with PCa have been identified in 
other parts of the receptor (Fig. 1). Tilley et al. for example, 
identified dual somatic missense mutations within the N-
terminal polyglutamine tract [75], which resulted in interrup-
tion of the tract by two leucine residues. These substitutions 
were found to reduce the ligand induced N- and C-terminal 
interaction, but paradoxically led to a receptor with greater 
activity than the wild-type AR. Coactivators have been de-
scribed that interact with the CAG repeat, for example 
ARA24 (Androgen Receptor-Associated Protein 24) [76], 
and it is believed that these mutations confer greater tran-
scriptional activity due to increased stability and folding of 
the tract, enhancing such interactions. This was demon-
strated by the finding that ARA24 was found to enhance 
activity of the mutant to a greater extent than the wild-type 
receptor [75]. It is possible that these enhanced interactions 
with coactivators may potentiate AR signalling in low levels 
of androgen or in the presence of weaker agonists and thus 
contribute to therapy failure.  
  Mutations have also been identified which disrupt an 
inhibitory domain located within the AR. The activity of AF-
2 has been demonstrated to be inhibited by the hinge region 
[77]. Haelens et al. have studied the effect of two mutations, 
R629Q and K630T, located in the hinge region of the AR. 
These mutations, which lie in the bipartite nuclear localisa-
tion signal, reduced nuclear localisation and DNA binding of 
the receptor. Surprisingly, however, the mutants had greater 
transcriptional activity than the wild-type receptor. Similarly 
Buchanan  et al. found that mutations Gln668Arg and 
Ile670Thr, also within the hinge region, also had increased 
activity and reduced ligand specificity compared to the wild-
type receptor without changes in receptor levels, ligand bind-
ing or DNA binding [78]. The data therefore suggests that 
mutations of the hinge region provide a growth advantage by 
increasing AR activity through disruption of an inhibitory 
domain. The exact mechanisms by which the hinge region 
inhibits the activity of AF-2 is yet to be elucidated, however, 
it has been postulated that the region may be inhibiting coac-
tivator interactions [19]. Hence, mutations of the hinge re-
gion may increase receptor activity by attenuating coactiva-
tor recruitment. 
2.4.2. Alterations in Ligand Specificity 
  The first AR variant with loss of ligand specificity to be 
described was a threonine to alanine substitution at amino 
acid 877 [79]. This mutant has since been frequently found 
in advanced prostatic carcinomas - Taplin et al. for example, 
found the mutation in 30% of bone marrow metastases [69]. 
The receptor not only responds to androgens but is also acti-
vated by oestrogens, progestins and the antiandrogens cypro-
terone acetate and hydroxyflutamide (the active form of flu-
tamide) [80]. Crystal structure analysis of the AR LBD has 
revealed that threonine 877 forms hydrogen bonds with the 
17-hydroxyl group of androgen [30]. Further modelling has 
demonstrated that substitutions to the smaller alanine affects 
the size and shape of the receptor such that other ligands can 
fit into the pocket and induce an active conformation [81]. 22    Current Genomics, 2009, Vol. 10, No. 1  Brooke and Bevan 
  Not all prostate cancer-associated substitutions in the 
LBD reduce ligand specificity by altering the dimensions of 
the pocket. The H874Y mutant AR, for example, is also ac-
tivated by hydroxyflutamide, oestradiol, progesterone, and 
cyproterone acetate, but the side chain of this residue points 
away from the pocket and is buried in a cavity between heli-
ces 11 and 12, which is formed following ligand induced 
activation [82]. This cavity is large enough to accommodate 
the tyrosine aromatic ring and hence it appears unlikely that 
the altered ligand specificity is as a result of steric alterations 
at this site. Instead, it appears that the more hydrophobic 
tyrosine side chain strengthens the interaction of helix 12 
with this groove. It has been proposed that this stronger in-
teraction could promote the relocation of helix 12 to the ac-
tive position even in the presence of a ligand that does not 
optimally fit into the pocket, thus reducing ligand specificity 
[82]. Interestingly, the mutant has been found to have en-
hanced binding to the p160 coactivators, suggesting that, in 
addition to broadened ligand specificity, the mutant receptor 
also has enhanced coactivator recruitment [83, 84]. 
  Differences in coactivator binding have also been found 
dependent upon which ‘agonist’ is activating the mutant re-
ceptor. As described previously, the AR can bind both 
LxxLL and phenylalanine-rich motifs (such as FxxLY), but 
has higher affinity for the latter. We have studied the prefer-
ence of several of the most commonly identified mutant re-
ceptors (H874Y, T877A and T877S) for these motifs and 
found striking differences in motif utilisation dependent 
upon which ligand is activating the receptor [85]. In the 
presence of cyproterone acetate, for example, the mutants 
specifically interact with the LxxLL motif whereas in the 
presence of hydroxyflutamide the receptor interacts with the 
FxxLY motif. Using chromatin immunoprecipitation, siRNA 
and target gene expression analysis, we were able to show 
that this selectivity extended to coactivator recruitment to 
endogenous genes demonstrating that dependent upon ligand 
and interaction motif, the mutant receptors may utilise dif-
ferent subsets of coactivators to potentiate gene expression. 
  The coactivator interaction groove of the AR is com-
prised of an L-shaped cleft comprised of three distinct sub-
sites (formed from helices 3, 4, 5 and 12 of the LBD) that 
bind hydrophobic groups at the +1, +4 and +5 positions in 
cognate peptides [47]. The conserved charge residues at ei-
ther end of the cleft, Lys702 and Glu897, form what is re-
ferred to as the “charge clamp” (Fig. 3). The charge clamp 
residues form electrostatic interactions with the main chain 
atoms at either end of phenylalanine-rich motifs whereas 
LxxLL motifs only form hydrogen bonds with Lys720. 
Charge clamp residue Glu897 is located in helix 12, the posi-
tioning of which is likely to be affected by the agonist 
bound. Therefore if an agonist is bound that does not induce 
the correct positioning of the charge clamp residues for in-
teraction with phenylalanine rich motifs, then the site ap-
pears to be available for LxxLL motif binding.  
  Several studies have demonstrated that inter- and intra-
receptor interactions made by the AR have differential ef-
fects dependent upon promoter context [86-88]. We hy-
pothesised that a mutant receptor activated by different ago-
nists could therefore regulate different subsets of genes, 
hence we studied the expression levels of genes involved in 
prostate differentiation (Kallikrein 2, KLK2, and Differentia-
tion Regulated Gene-1, DRG-1) and cell cycle progression 
(Cyclin Dependent Kinases 2 and 4, CDK2 and CDK4) in 
the LNCaP prostate cancer cell line, which endogenously 
expresses the T877A mutant AR [85]. The expression of 
KLK2 and CDK2 in response to different ligands was similar 
– induced most strongly by androgen, then the antiandrogen 
hydroxyflutamide then cyproterone acetate. Evidence of 
CDK4 being an androgen-regulated gene is contradictory, 
with upregulation in response to androgen reported in some 
studies [89] but not found in others [90]. In agreement with 
the latter we found no induction of CDK4 in response to an-
drogen, but interestingly the two antiandrogens did induce 
expression. Even more striking was the regulation of DRG-1, 
which we found to be highly upregulated by androgen (more 
than 12-fold) and only weakly by hydroxyflutamide (ap-
proximately 1.7-fold). Hence the mutant AR induced differ-
ent “patterns” of regulation of a subset of androgen-regulated 
genes according to the ligand. Since this includes genes that 
are involved in tumour growth, there may be implications for 
tumour progression and treatment. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Surface representation of the AR coactivator groove. 
Representation of the AR AF-2 surface highlighting the L-shaped 
cleft and key residues important in coactivator binding. +1, +4 and 
+5 refer to the regions in which the 1
st, 4
th and 5
th amino acids of 
LxxLL and FxxLF-like motifs lie following binding. Image created 
using RasMol V2.6 using co-ordinates from [30]. 
3. IMPLICATIONS FOR THE TREATMENT OF 
PROSTATE CANCER 
  The findings summarised here have important implica-
tions for the treatment of prostate cancer. The data suggest 
that tumours may behave differently dependent upon (i) 
which mutation, if any, is present and (ii) which ligand is 
driving growth, since different subsets of genes may be regu-
lated. We suggest that it would therefore be useful to screen 
patients for AR mutations following hormone therapy fail-
ure, so that subsequent treatment could be adjusted accord-
ingly. Understanding of how AR mutations alter androgen 
signalling at the molecular level will also be useful in the 
development of novel therapies, in particular Selective An-
drogen Receptor Modulators (SARMs). Knowledge of how 
such molecules affect the structure of the AR, interactions 
that the receptor makes and subsequently gene expression 
could aid in designing drugs that regulate certain subsets of 
genes. For example, it would be desirable to design a SARM 
that blocks expression of androgen target genes that promote The Role of Androgen Receptor Mutations in Prostate Cancer Progression  Current Genomics, 2009, Vol. 10, No. 1    23 
tumour growth, whilst up-regulating transcription of benefi-
cial genes (for example those important for maintenance of 
bone density).  
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